This review focuses on immune checkpoint inhibitors–immunomodulatory agents that aim to
relieve tumour-mediated immune-cell suppression. Immune checkpoint proteins can be …

Immunotherapy is revolutionizing cancer treatment; however, complete responses are
achieved in only a small fraction of patients and tumor types. Thus, there is an urgent need …

First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …

Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the
first-line treatment of advanced non-small-cell lung cancer with programmed cell death …

Background No systemic therapies have been approved for the treatment of advanced
cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy …

Background Cemiplimab has shown substantial antitumour activity in patients with
metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous …

Original research: Phase 2 study of cemiplimab in patients with metastatic cutaneous
squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based …

Background To provide pooled longer term data from three groups of a phase 2 study of
cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to …

Cemiplimab (LIBTAYO®; cemiplimab-rwlc), a human programmed death receptor-1 (PD-1)
monoclonal antibody that binds to PD-1 and blocks its interaction with programmed death …

Non-melanoma skin cancers are cutaneous malignancies representing the most common
form of cancer in the United States. They are comprised predominantly of basal cell …